(redirected from Allergy immunotherapy)
Also found in: Encyclopedia.


1. the prevention or reduction of immediate hypersensitivity by administration of graded doses of allergen; see also immunotherapy. Called also hyposensitization.
2. in behavior therapy, the treatment of phobias and related disorders by intentionally exposing the patient, in imagination or in real life, to a hierarchy of emotionally distressing stimuli.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.


1. The reduction or abolition of allergic sensitivity or reactions to the specific antigen (allergen). Synonym(s): antianaphylaxis
2. The act of removing an emotional complex.
Synonym(s): hyposensitization
Farlex Partner Medical Dictionary © Farlex 2012


Allergen immunotherapy, see there.
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.
References in periodicals archive ?
[ClickPress, Thu Aug 29 2019] This report studies the current as well as future prospects of the global Allergy Immunotherapy Market .
Allergy immunotherapy helps in reducing inflammation, offering long-term impact, increasing immunological tolerance, changing the course of the disease and improving the quality of the patient's life.
If approved, INT301 has the potential to be the first allergy immunotherapy treatment that easily integrates into a person's daily routine as both first line and long-term maintenance therapy for peanut allergy.
Also, the data used in the filing was among the strongest pollen trial results ever seen in field studies of allergy immunotherapy. These include results from the phase III clinical trial finalised in 2017 with ITULAZAX.
> Diagnose allergies that are amenable to allergy immunotherapy (AIT) using skin prick/puncture allergy testing in conjunction with clinical symptoms, triggers, and exposure, (A)
Thanks to its innovative ASIT+ technology platform, ASIT biotech is currently the only developer of allergy immunotherapy (AIT) product candidates consisting of a unique mixture of highly purified natural allergen fragments in an optimal size selection.
In 2018, we will continue to focus on commercial execution, optimizing our current product portfolio to gain further market share, and developing new offerings to expand allergy immunotherapy penetration in market segments where we see growth opportunities.
Stallergenes Greer plc is a global healthcare company specialising in the diagnosis and treatment of allergies through the development and commercialisation of allergy immunotherapy products and services.
Although HDM allergic rhinitis can be treated symptomatically with oral antihistamines and nasal steroids, allergy immunotherapy has the appeal of addressing the underlying disease mechanism and potentially altering the long-term course.
The closest thing to a cure is allergy immunotherapy, a means of building up tolerance to allergies by taking increasing dosages of allergic substances, similar to immunization for the flu.

Full browser ?